Skip NavigationSkip to Content

Vector order determines protection against pathogenic simian immunodeficiency virus infection in a triple component vaccine by balancing CD4(+) and CD8(+) T-cell responses

  1. Author:
    Sauermann, Ulrike
    Radaelli, Antonia
    Stolte-Leeb, Nicole
    Raue, Katharina
    Bissa, Massimiliano
    Zanotto, Carlo
    Krawczak, Michael
    Tenbusch, Matthias
    Überla, Klaus
    Keele, Brandon
    De Giuli Morghen, Carlo
    Sopper, Sieghart
    Stahl-Hennig, Christiane
  2. Author Address

    Unit of Infection Models, Deutsches Primatenzentrum GmbH, Goettingen, Germany., Department of Pharmacological and Biomolecular Sciences, University of Milano, Milano, Italy., Department of Medical Biotechnologies and Translational Medicine, University of Milano, Milano, Italy., Institute of Medical Informatics and Statistics, Christian-Albrechts University, Kiel, Germany., Department of Molecular and Medical Virology, Ruhr University Bochum, Bochum, Germany., AIDS and Cancer Virus Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA., Catholic University "Our Lady of Good Counsel", Tirana, Albania., Clinic for Hematology and Oncology, Medical University Innsbruck, Tyrolean Cancer Research Center, Innsbruck, Austria ., Unit of Infection Models, Deutsches Primatenzentrum GmbH, Goettingen, Germany stahlh@dpz.eu.,
    1. Year: 2017
    2. Date: Dec
    3. Epub Date: 2017 Sep 13
  1. Journal: Journal of Virology
    1. 91
    2. 23
    3. Pages: e01120-17
  2. Type of Article: Article
  3. Article Number: e01120-17
  1. Abstract:

    An effective AIDS vaccine should elicit strong humoral and cellular immune responses while maintaining low levels of CD4(+) T cell activation to avoid the generation of target cells for viral infection. The present study investigated two prime-boost regimens, both starting vaccination with single cycle immunodeficiency virus, followed by two mucosal boosts either with recombinant adenovirus (rAd) or fowlpox virus (rFWPV) expressing SIVmac239 or SIVmac251 gag/pol and env genes, respectively. Finally, vectors were switched and systemically administered to the reciprocal group of animals. Only mucosal rFWPV immunizations followed by systemic rAd boost significantly protected animals against a repeated low-dose, intrarectal challenge with pathogenic SIVmac251 resulting in a vaccine efficacy (i.e. risk reduction per exposure) of 68%. Delayed viral acquisition was associated with higher levels of activated CD8(+) T cells and Gag-specific IFN-? secreting CD8(+) cells, low virus-specific CD4(+) T cell responses and low Env antibody titers. In contrast, the systemic rFWPV boost induced strong virus-specific CD4(+) T cell activity. rAd and rFWPV also induced differential patterns of the innate immune responses, thereby possibly shaping the specific immunity. Plasma CXCL10 levels after final immunization correlated directly with virus-specific CD4(+) T cell responses and inversely with the number of exposures to infection. Also, the percentage of activated CD69(+) CD8(+) T cells correlated with the number of exposures to infection. Differential stimulation of the immune response likely provided the basis for the diverging levels of protection afforded by this vaccine regimen.IMPORTANCE A failed phase II AIDS vaccine trial led to the hypothesis that CD4(+) T cell activation can abrogate any potentially protective effects delivered by vaccination or promote acquisition of the virus because CD4(+) T helper cells, required for an effective immune response, also represent the target cells for viral infection. We compared two vaccination protocols that elicited similar levels of Gag-specific immune responses in rhesus macaques. Only the animal group that had a low level of virus-specific CD4(+) T cells in combination with high levels of activated CD8(+) T cells was significantly protected from infection. Notably, protection was achieved despite the lack of appreciable Env-antibody titers. Moreover, we show that both, the vector and the route of immunization affected the level of CD4(+) T cell responses. Thus, mucosal immunization with FWPV-based vaccines should be considered as potent prime in prime-boost vaccination protocols. Copyright © 2017 American Society for Microbiology.

    See More

External Sources

  1. DOI: 10.1128/JVI.01120-17
  2. PMID: 28904195
  3. PMCID: PMC5686736
  4. WOS: 000415289800017

Library Notes

  1. Fiscal Year: FY2016-2017
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel